The accuracy of prostate-specific antigen (PSA) screening can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to a multi-centre study in the US.
In a study led by UC San Francisco (UCSF) and Stanford University which was published on June 1, 2023 in Nature Medicine, the researchers and their collaborators conducted a large genome-wide association study of PSA in more than 95,000 men without diagnosed prostate cancer, which identified over 80 novel PSA-associated variations.